NPS Pharmaceuticals Earnings: Here’s Why Investors are Not Happy Now

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 0.63%.

NPS Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.14 in the quarter versus EPS of $-0.10 in the year-earlier quarter.

Revenue: Rose 3.2% to $27.1 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: NPS Pharmaceuticals, Inc. reported adjusted EPS loss of $0.14 per share. By that measure, the company missed the mean analyst estimate of $-0.09. It missed the average revenue estimate of $28.93 million.

Quoting Management: “We executed our business plan exceptionally well in 2012 and secured FDA approval of our first proprietary product, Gattex®,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “The launch of Gattex is underway as the first and only long-term treatment for adult short bowel syndrome, an ultra-orphan and highly debilitating disorder. Gattex has tremendous potential to transform patients’ lives and grow our business substantially. In the year ahead, we look forward to providing updates on our launch progress, reporting results from our STEPS 2 study, and beginning a pediatric development program for Gattex. We are also preparing for other important milestones including the submission of our Biologics License Application for our second proprietary product, Natpara®, as the first replacement therapy for hypoparathyroidism.”

Key Stats (on next page)…